Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR®

Growth Hormone and IGF Research

Volumn 17, Issue 1, 2007, Pages 77-81

  Taboada, Giselle Fernandes ^a   Correa, Lívia Lugarinho ^a,b   Machado, Evelyn de Oliveira ^a   Haute, Flávia Regina van ^a   Casini, Alessandra Ferri ^a   Balarini, Giovanna Aparecida ^a,b   Neto, Leonardo Vieira ^a   Calixto, Lilia ^c   Calixto, Cláudia ^c   Gadelha, Mônica Roberto ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c Laboratorio Diagnosticos da America   (Brazil)

Author keywords

Acromegaly; Basal GH; Mean GH; Octreotide LAR

Indexed keywords

GROWTH HORMONE; OCTREOTIDE;

ACROMEGALY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE CONTROL; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; BLOOD SPECIMEN COLLECTION; CLINICAL PROTOCOLS; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; ROC CURVE; TIME FACTORS;

EID: 33847294823     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.12.003     Document Type: Article

References (26)

1. Cone R.D., Low M.J., Elmquist J.K., and Cameron J.L. Neuroendocrinology. In: Larsen P.R., Kronenberg H.M., Melmed S., and Polonsky K.S. (Eds). Williams Textbook of Endocrinology. 10th ed. (2003), W.B. Saunders, Philadelphia 81-176
2. Stolar M.W., and Baumann G. Secretory patterns of growth hormone during basal periods in man. Metabolism 35 (1986) 883-888
3. Winer L.M., Shaw M.A., and Baumann G. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J. Clin. Endocrinol. Metab. 70 (1990) 1678-1686
4. Hartman M.L., Veldhuis J.D., Vance M.L., Faria A.C., Furlanetto R.W., and Thorner M.O. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J. Clin. Endocrinol. Metab. 70 (1990) 1375-1384
5. Semer M., Faria A.C., Nery M., et al. Growth hormone pulsatility in active and cured acromegalic subjects. J. Clin. Endocrinol. Metab. 80 (1995) 3767-3770
6. Van Den Berghe G., Frolich N., Veldhuis J.D., and Roelfsema F. Growth hormone secretion in recently operated acromegalic patients. J. Clin. Endocrinol. Metab. 79 (1994) 1706-1715
7. Ho P.J., Jaffe C.A., Friberg R.D., Chandler W.F., and Barkan A.L. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J. Clin. Endocrinol. Metab. 78 (1994) 1403-1410
8. Ho K.K.Y., and Weissberger A.J. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin. Endocrinol. 41 (1994) 75-83
9. Barkan A.L., Stred S.E., Reno K., et al. Increased growth hormone pulse frequency in acromegaly. J. Clin. Endocrinol. Metab. 69 (1989) 1225-1233
10. Peacey S.R., Toogood A.A., Veldhuis J.D., Thorner M.O., and Shalet S.M. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J. Clin. Endocrinol. Metab. 86 (2001) 259-266
11. Resmini E., Barreca A., Ferone D., Giusti M., Sidoti M., and Minuto F. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. Clin. Endocrinol. 63 (2005) 294-297
12. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85 (2000) 526-559
13. Melmed S., Casanueva F., Cavagnini F., et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153 (2005) 737-740
14. Colao A., Attanasio R., Pivonello R., et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 91 (2006) 85-92
15. Cozzi R., Montini M., Attanasio R., et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab. 91 (2006) 1397-1403
16. Colao A., Pivonello R., Rosato F., et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol. 64 (2006) 342-351
17. Colao A., Pivonello R., Cappabianca P., et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin. Endocrinol. 63 (2005) 342-349
18. ® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. 60 (2004) 375-381
19. Biermasz N.R., van der Oever N.C., Frölich M., et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin. Endocrinol. 58 (2003) 288-295
20. Bevan J.S., Atkin S.L., Atkinson A.B., et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release Octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab. 87 (2002) 4554-4563
21. Newman C.B., Melmed S., George A., et al. Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metab. 83 (1998) 3034-3040
22. Davies P.H., Stewart S.E., Lancranjan L., Sheppard M.C., and Stewart P.M. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin. Endocrinol. 48 (1998) 311-316
23. Flogstad A.K., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns C.H., and Jervell J. Sandostatin LAR in acromegalic patients: long term treatment. J. Clin. Endocrinol. Metab. 81 (1997) 23-28
24. Kaltsas G.A., Isidori A.M., Florakis D., et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J. Clin. Endocrinol. Metab. 86 (2001) 1645-1652
25. Colao A., Pivonello R., Cavallo L.M., Gaccione M., Auriemma R.S., Esposito F., Cappabianca P., and Lombarda G. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin. Endocrinol. 65 (2006) 250-256
26. Wass J.A.H. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. J. Endocrinol. 155 (1997) S17-S19